



## Advaxis Announces Four Poster Presentations Highlighting Lm-based Antigen Delivery Technology at AACR 2018

March 26, 2018

*Including Three Late-Breaking Poster Presentations*

PRINCETON, N.J.--(BUSINESS WIRE)-- [Advaxis, Inc.](#) (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that results from multiple preclinical studies of its *Lm*-based antigen delivery technology will be presented at the American Association for Cancer Research Annual Meeting 2018 (AACR 2018), April 14-18, 2018 in Chicago.

The following late-breaking research will be presented:

**Poster Title:** Neoantigens that fail to elicit measurable T cell responses following peptide immunization can control tumor growth when delivered using a *Listeria*-based immunotherapy platform

**Poster Number:** LB-150/17

**Session Title:** Late-Breaking Research: Clinical Research

**Session Date and Time:** Monday, April 16, 2018, 1:00 pm - 5:00 pm (CT)

**Authored By:** Advaxis and Amgen

**Poster Title:** [Targeting frameshift mutations with a \*Listeria monocytogenes\* immunotherapy drives neoantigen-specific antitumor immunity in the MC38 and CT26 mouse tumor models](#)

**Poster Number:** LB-148/15

**Session Title:** Late-Breaking Research: Clinical Research

**Session Date and Time:** Monday, April 16, 2018, 1:00 pm - 5:00 pm (CT)

**Authored By:** Advaxis and Amgen

**Poster Title:** [Targeting shared hotspot cancer mutations with a \*Listeria monocytogenes\* immunotherapy induces potent anti-tumor immunity](#)

**Poster Number:** LB-149/16

**Session Title:** Late-Breaking Research: Clinical Research

**Session Date and Time:** Monday, April 16, 2018, 1:00 pm - 5:00 pm (CT)

**Authored By:** Advaxis

In addition, the following Investigator Sponsored Trial data will be presented:

**Poster Title:** Changes in local and peripheral T cell diversity after HPV E7 antigen-expressing *Listeria*-based immunotherapy (ADXS11-001) prior to robotic surgery for HPV-positive oropharyngeal cancer

**Poster Number:** 5639/10

**Session Title:** PO.CL06.11: Vaccines 2

**Session Date and Time:** Wednesday, April 18, 2018, 8:00 am - 12:00 pm (CT)

**Authored By:** Andrew Sikora, Ph.D., MD, co-director of the Head and Neck Cancer Program at Baylor College of Medicine

#### **About Advaxis, Inc.**

Advaxis, Inc. is a late-stage biotechnology company focused on the discovery, development and commercialization of proprietary *Lm*-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated *Listeria monocytogenes (Lm)* bioengineered to secrete antigen/adjuvant fusion proteins. These *Lm*-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T cells to eliminate tumors. Advaxis has four franchises in various stages of clinical and preclinical development: HPV-associated cancers, neoantigen therapy, hotspot/ cancer antigens and prostate cancer.

To learn more about Advaxis, visit [www.advaxis.com](http://www.advaxis.com) and connect on [Twitter](#), [LinkedIn](#), [Facebook](#), and [YouTube](#).

#### **Advaxis Forward-Looking Statement**

This press release contains forward-looking statements, including, but not limited to, statements regarding Advaxis' ability to develop and commercialize the next generation of cancer immunotherapies, and the safety and efficacy of Advaxis' proprietary immunotherapies. These forward-looking statements are subject to a number of risks including the risk factors set forth from time to time in Advaxis' SEC filings including, but not limited to, its report on Form 10-K for the fiscal year ended October 31, 2017, and on Form 10-Q for the quarter ended January 31, 2018, which are available at [www.sec.gov](http://www.sec.gov).

Any forward-looking statements set forth in this presentation speak only as of the date of this presentation. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof other than as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

#### **CONTACT:**

Company:

[Advaxis, Inc.](http://Advaxis, Inc.)

Noelle Heber, 609-250-7575

Sr. Director Corporate Communications and Government Affairs

[Heber@advaxis.com](mailto:Heber@advaxis.com)

or

Media:

[Stern Strategy Group](#)

Brian Hyland, 908-325-3891

[Bhyland@sternstrategy.com](mailto:Bhyland@sternstrategy.com)

or

Rachel Auerbach, 908-325-3898

[Rauerbach@sternstrategy.com](mailto:Rauerbach@sternstrategy.com)

or

Investors:

[LHA Investor Relations](#)

Anne Marie Fields, 212-838-3777

[afields@lhai.com](mailto:afields@lhai.com)